Taiwan cancer drugs developer seeks Hong Kong bond issue ahead of IPO after delisting from Taipei

JHL Biotech, a Taiwan developer of cheaper alternatives to patent-protected biological drugs, has raised US$106 million from a convertible bond issue, ahead of its planned Hong Kong initial public offering (IPO) aiming to raise some US$250 million.
( read original story …)


Related Post

Hong Kong paralympian applies sports dedication to...
views 17
When the elite wheelchair athlete is not training ...
China’s Greater Bay Area scheme opens up doors for...
views 18
Hong Kong’s arts and culture sector has been takin...
Should Hong Kong say goodbye to public phone booth...
views 20
When was the last time you used a public payphone?...
Hong Kong rugby team’s rousing rendition of China’...
views 17
Before the start of the match when March of the Vo...
ID card replacement to start
views 25
Hong Kong residents born in 1985 or 1986 can apply...
Hong Kong police urged to pursue attack on Hong Ko...
views 26
A legislator has urged Hong Kong police to investi...
Mega project for 9,500 private flats in Hong Kong’...
views 26
Town planning authorities have given the final app...
Analysts upbeat about China’s equity market ...
views 26
Ricky Choi Wing-hung, a senior economist from Bank...
Reciprocal deal between Hong Kong and mainland Chi...
views 26
Hong Kong and mainland China signed a reciprocal d...
Scammers swindle Hong Kong man out of HK$430,000 i...
views 30
A 48-year-old man has become the biggest victim of...